PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial

BACKGROUND: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States who have previously responded to injectable somatostatin receptor ligands (iSRLs, octreotide or lanreotide). In previous phase 3 studies, the safety of OOC was shown to be consistent w...

Descripción completa

Detalles Bibliográficos
Autores principales: Elenkova, Atanaska, Jensterle, Mojca, Kennedy, Laurence, Manning, Patrick, Melmed, Shlomo, Strasburger, Christian J, Samson, Susan, Nachtigall, Lisa, Fleseriu, Maria, Molitch, Mark E, Giustina, Andrea, Haviv, Asi, Biermasz, Nienke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625665/
http://dx.doi.org/10.1210/jendso/bvac150.1138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625665/
http://dx.doi.org/10.1210/jendso/bvac150.1138

Ejemplares similares